Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Previous participation in NN7999-3747 (NCT01333111) and/or NN7999-3773~Exclusion Criteria:~* Known history of FIX inhibitors based on existing medical records, laboratory report reviews and patient and LAR (legal acceptable representative) interviews~* Current FIX inhibitors above or equal to 0.6 BU (Bethesda Units)~* Congenital or acquired coagulation disorders other than haemophilia B~* Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records)~* Any disease (liver, kidney, inflammatory and mental disorders included) or condition which, according to the Investigator's (trial physician) judgement, could imply a potential hazard to the patient, interfere with trial participation, or interfere with trial outcome

- Gender: MALE
- Minimum Age: 13 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis, high dose (once weekly) (Type: EXPERIMENTAL): None
- Prophylaxis, low dose (once weekly) (Type: EXPERIMENTAL): None
- On-demand (Type: EXPERIMENTAL): None
- Prophylaxis, high dose (every second week) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).